Přehled o publikaci
2023
Circulating tumor cell-derived preclinical models: current status and future perspectives
KAHOUNOVÁ, Zuzana; Markéta PÍCKOVÁ; Stanislav DRÁPELA; Jan BOUCHAL; Eva SZCZYRBOVÁ et al.Basic information
Original name
Circulating tumor cell-derived preclinical models: current status and future perspectives
Authors
KAHOUNOVÁ, Zuzana; Markéta PÍCKOVÁ; Stanislav DRÁPELA; Jan BOUCHAL; Eva SZCZYRBOVÁ; Jiří NAVRÁTIL and Karel SOUČEK
Edition
DISEASE, LONDON, NATURE PUBLISHING GROUP, 2023, 2041-4889
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
References:
Marked to be transferred to RIV
No
Organization
Přírodovědecká fakulta – Repository – Repository
UT WoS
EID Scopus
Keywords in English
METASTATIC BREAST-CANCER; EX-VIVO CULTURE; PERIPHERAL-BLOOD; PROGRESSION-FREE; LIQUID BIOPSIES; VENOUS-BLOOD; LUNG; SURVIVAL; STAGE; ESTABLISHMENT
Links
LX22NPO5102, research and development project.
Changed: 17/1/2024 03:44, RNDr. Daniel Jakubík
Abstract
In the original language
Despite the advancements made in the diagnosis and treatment of cancer, the stages associated with metastasis remain largely incurable and represent the primary cause of cancer-related deaths. The dissemination of cancer is facilitated by circulating tumor cells (CTCs), which originate from the primary tumor or metastatic sites and enter the bloodstream, subsequently spreading to distant parts of the body. CTCs have garnered significant attention in research due to their accessibility in peripheral blood, despite their low abundance. They are being extensively studied to gain a deeper understanding of the mechanisms underlying cancer dissemination and to identify effective therapeutic strategies for advanced stages of the disease. Therefore, substantial efforts have been directed towards establishing and characterizing relevant experimental models derived from CTCs, aiming to provide relevant tools for research. In this review, we provide an overview of recent progress in the establishment of preclinical CTC-derived models, such as CTC-derived xenografts (CDX) and cell cultures, which show promise for the study of CTCs. We discuss the advantages and limitations of these models and conclude by summarizing the potential future use of CTCs and CTC-derived models in cancer treatment decisions and their utility as precision medicine tools.